Skip to main content

Drug Interactions between ATryn and caplacizumab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

antithrombin recombinant caplacizumab

Applies to: ATryn (antithrombin (recombinant)) and caplacizumab

MONITOR CLOSELY: Concomitant use of caplacizumab with other agents that affect hemostasis such as anticoagulants, platelet aggregation inhibitors, thrombolytic agents, or drugs that cause thrombocytopenia may increase the risk of bleeding. In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of subjects treated with caplacizumab. Overall, bleeding events occurred in approximately 58% of patients on caplacizumab versus 43% of patients on placebo. The risk of bleeding is increased in patients with underlying coagulopathies (e.g. hemophilia, other coagulation factor deficiencies) or concomitant use of drugs affecting hemostasis and coagulation.

MANAGEMENT: Caution is recommended if caplacizumab must be used with other agents that affect hemostasis. Patients should be monitored for potential bleeding complications and therapy interrupted if clinically significant bleeding occurs. If needed, von Willebrand factor concentrate may be administered to rapidly correct hemostasis.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Cablivi (caplacizumab)." Genzyme Corporation (2019):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer